1. INITIAL PRESENTATION OF RECURRENT UTI

The widely accepted definition of ‘recurrent UTI’ in women are three or more episodes of UTI in 12 months or two or more episodes of lower UTI in 6 months. This does not include episodes of bacteriuria without UTI symptoms (asymptomatic bacteriuria). The following measures to limit UTI should be considered prior to commencement of antibiotic prophylaxis:

- Encourage better hydration (1.6L/day recommended) to ensure more frequent urination as this can reduce recurrence (see ref 11)
- Encourage urge initiated voiding and postcoital voiding. Advise sexually active women that diaphragm and spermicide use are risk factors for cystitis and discuss alternative contraception
- Advise the patient to obtain and try cranberry products (avoid if on warfarin) or d-mannose to reduce recurrence
- Offer a prescription for a ‘stand-by’ antibiotic to be taken at the first symptoms of UTI
- For recurrent cystitis associated with sexual intercourse: offer trimethoprim 100mg to be taken within 2 hours of intercourse (off-label use)
- For post-menopausal women with risk factors such as atrophic vaginitis consider prescribing intravaginal oestrogen. Review within 12 months
- For post-menopausal women with no obvious risk factors, consider referral to urology for further investigations, particularly if recurrent UTI is a recent problem

If these simple measures fail to improve symptoms then follow the flow chart below:

- Check MSU to confirm diagnosis and establish sensitivities during acute UTI episode
- If continued problems consider renal tract ultrasound (to detect stones, cysts, tumours and other abnormalities) and post void bladder residual volume scan (to detect voiding dysfunction)
- If investigations normal and continued problems consider prescribing low dose prophylactic antibiotics as per local guidance for a 3-6 month period, then review ongoing need
- If new presentation in post-menopausal women also consider referral for cystoscopy to determine if symptoms are due to an intravesical lesion e.g. stone or tumour

December 2018     For review December 2021
Based on original guidance produced by NHS Tayside
Counselling prior to initiation of prophylaxis

The patient should be counselled at an early stage that antibiotic prophylaxis is prescribed for a fixed period of time not usually a life-long treatment. Antibiotic prophylaxis should not be considered in patients with indwelling catheters. Antibiotics are given in this way to allow a period of bladder healing which makes UTI much less likely. There is no evidence they have any additional benefit beyond 3-6 months treatment therefore the treatment should be discontinued ideally after 6 months. Rotation of prophylactic antibiotics to address issues of resistance is not encouraged. This patient information leaflet on recurrent UTI may be helpful [http://patient.info/pdf/4437.pdf](http://patient.info/pdf/4437.pdf)

2. STOPPING A PROLONGED COURSE OF PROPHYLACTIC ANTIBIOTICS

Identifying patients for review

Patients should be reviewed after 3-6 months of prophylactic antibiotics with a view to stopping them and it may be helpful to document a review date in the medical notes and also on the prescription. For audit purposes and retrospective review 6 months is suggested as a suitable trigger for prolonged duration.

Discussing patient concerns

Patients may feel anxious about returning to suffering recurrent UTIs. However after a prolonged period of antibiotic treatment in most cases this has allowed the bladder wall to ‘heal’ making UTIs less likely. They should be given appropriate advice regarding continuation of simple measures to prevent UTI. The risks of long term antibiotics in terms of vulvovaginal side effects, *Clostridium difficile* and increased likelihood of infection with resistant organisms are also important considerations for the doctor and patient and should be fully discussed. The importance of adequate hydration and its potential role in preventing UTI should be discussed.

Recurrence of UTI after stopping antibiotic prophylaxis

It is important to ensure the patient is complying as far as possible with the simple measures outlined previously.

If they have not already had a renal tract ultrasound and post void bladder residual volume scan now is a good time to consider doing this in consultation with local specialists.

In post-menopausal women consider the possibility of atrophic vaginitis as a risk factor for UTI and manage appropriately. If recurrent UTI is a relatively ‘new’ problem in a post-menopausal woman consideration should also be given to referral for cystoscopy.

However, if appropriate investigations have already been done and shown no abnormality and there are no other concerning ‘red flag’ symptoms and cranberry extract has already been tried (or is inappropriate e.g. if the patient is on warfarin) then continuation of prophylaxis may be considered. The ongoing need for antibiotic prophylaxis should be reviewed again after 3 months.

Non-antibiotic therapies

The recent NICE guidance concludes the following:

**Cranberry products**: These are used widely and very low quality evidence (see ref 12) shows some benefit for reducing the risk of UTIs in non-pregnant women. No evidence to suggest benefit in older women.

**Probiotics**: There is inconclusive evidence to recommend the use of lactobacillus to prevent recurrent UTIs.

**D-mannose**: Evidence from 1 small RCT suggests D-mannose may be effective in reducing the risk of recurrent UTI in non-pregnant women. The NNT was 3 (range 2 to 3) over 6 months, compared with no treatment.

Other therapies with some evidence include:

**Methenamine**: May be effective for short term prophylaxis in patients without renal tract abnormalities. For longer term prophylaxis the evidence is poor.

**Immunoactive prophylaxis**: Uro-Vaxom® is more effective than placebo in female patients with recurrent uncomplicated UTI and has a good safety profile. It is unlicensed in the UK. There is insufficient evidence about other vaccines.
References

European Association of Urology http://uroweb.org/guideline/urological-infections/#3_5


[3] Prevention of recurrent urinary tract infections in women

[4] Recurrent urinary tract infections in women

The Cochrane Library (2008)

[6] Scenario: Recurrent UTI – (no visible haematuria, not pregnant or catheterized)
CKS NICE (2015)

Scottish Intercollegiate Guidelines Network 88 (2012)

[8] Urinary tract infection (recurrent): antimicrobial prescribing
National Institute for Health and Care Excellence 2018

The Cochrane Library 2012

[10] A retrospective study of immunotherapy treatment with Uro-Vaxom® (OM-89) for prophylaxis of recurrent urinary tract infections
Eur Urol Suppl 2017; 16(3);e238

A Randomized Clinical Trial
JAMA Intern Med. 2018;178(11):1509-1515